Wegovy Pill Tracker: Daily Oral Semaglutide Log

A Wegovy pill tracker is a daily log for oral semaglutide that records the dose, time taken, missed doses, food-and-water timing, side effects, and weight progress. In the US, FDA documents now include Wegovy tablets as an approved prescription option for certain adults, but tracking should follow the exact instructions from your prescriber and the FDA label.

The main difference from weekly Wegovy injection tracking is frequency. A tablet routine creates seven medication decisions per week, so a tracker needs to make daily adherence, missed-dose notes, and side-effect patterns easy to review.

Quick answer: Track Wegovy tablets by logging the tablet strength, time taken, whether you waited before food or other oral medicines, side effects, weight changes, and any missed doses. If you are switching from injections or another GLP-1 medicine, follow your prescriber's instructions instead of using an app log to decide timing.

Is there an FDA-approved Wegovy pill in the US?

Yes. The FDA approved Wegovy (semaglutide) tablets under NDA 218316 for use with a reduced-calorie diet and increased physical activity in certain adults. The FDA approval letter lists adult weight reduction and adult cardiovascular risk reduction indications; the prescribing information gives the oral tablet dosing schedule.

FDA approval scope

FDA's approval letter for Wegovy tablets says the product is approved for adults with obesity or adults with overweight and at least one weight-related comorbid condition, and for reducing major adverse cardiovascular event risk in adults with established cardiovascular disease and either obesity or overweight.

The current Wegovy prescribing information lists both injection and tablet forms. For tablets, the label starts at 1.5 mg once daily for 30 days, then 4 mg, then 9 mg, with 25 mg once daily as the recommended maintenance dosage for adult cardiovascular risk reduction or weight reduction.

Wegovy pill status: As of the FDA-approved labeling available for this April 27, 2026 post, Wegovy tablets are an FDA-approved oral semaglutide product in the US for specific adult indications. That does not mean every patient should use tablets or that every pharmacy, insurer, or prescriber will handle access the same way.

Wegovy tablet tracking vs Rybelsus tracking

Wegovy tablets and Rybelsus tablets both contain semaglutide, but they are not the same prescription product or the same use case. Rybelsus is labeled for adults with type 2 diabetes, including glycemic control and cardiovascular risk reduction in high-risk adults with type 2 diabetes. Wegovy tablets are labeled for adult weight reduction and adult cardiovascular risk reduction in the Wegovy population described by FDA.

That distinction matters for a tracker because the medication name, strength, goal, and prescriber instructions should match the prescription bottle. Do not relabel a diabetes medication as a weight-loss medication in your log just because the active ingredient overlaps.

Match the prescription label

Your tracker should match the exact medication your clinician prescribed because semaglutide products are not interchangeable just because they share an active ingredient. The Wegovy label also says Wegovy should not be used with other semaglutide-containing products or other GLP-1 receptor agonists.

Write the brand, form, strength, and schedule exactly as prescribed: for example, "Wegovy tablet 4 mg, morning" rather than "semaglutide pill." Specific logs reduce confusion when you refill, message your care team, or review side effects after a dose change.

What should a Wegovy pill tracker record each day?

A useful Wegovy pill tracker records the daily dose, time taken, administration timing, missed-dose status, side effects, weight trend, and relevant habit notes. The goal is not to create a perfect diary; it is to preserve the details your future self and clinician will actually need.

Dose, strength, and escalation day

Log the exact tablet strength and the day of your current escalation step because Wegovy tablets move through multiple strengths before maintenance. The FDA label lists 1.5 mg for days 1 through 30, 4 mg for days 31 through 60, 9 mg for days 61 through 90, and 25 mg from day 91 onward.

That schedule is a label-based reference, not a personal instruction to increase without clinician guidance. If your prescriber delays escalation because of side effects or changes your plan, your tracker should reflect the customized plan. GlucoPal supports daily Wegovy pill tracking, so the tablet routine does not have to be forced into a weekly injection calendar.

Morning timing and the wait before food

Track when you take the tablet and when you first eat, drink, or take other oral medicines. Wegovy tablet labeling says to take one tablet once daily on an empty stomach in the morning with up to 4 ounces of water, then wait at least 30 minutes before food, beverages, or other oral medications.

For Wegovy tablets, your prescriber's instructions and the current label should be your source of truth. A practical tracker field is simple: "took pill," "waited before food," and "other morning meds." That is easier to keep up than writing a paragraph every day.

Missed doses and skipped days

A Wegovy pill tracker should record missed doses without encouraging make-up dosing. The Wegovy label says that if a Wegovy tablet dose is missed, skip the missed dose and take the next dose the following day.

This is one of the places where daily pill tracking is more useful than memory. A missed day can feel obvious in the moment and become fuzzy by the weekend. Record it as "missed, skipped per label/prescriber plan" rather than leaving a blank that you might later misread.

Symptoms, weight, and nutrition context

Track symptoms beside the dose date because GI effects, appetite changes, and dose escalation can overlap. The Wegovy label lists common adverse reactions such as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, low blood sugar in patients with diabetes, gas, gastroenteritis, reflux, and common cold symptoms.

The most useful symptom note is short and specific: "nausea after breakfast, mild, day 3 at 4 mg" is more helpful than "felt bad." GlucoPal's symptom journal lets you log side effects next to dose history, which can make appointment notes easier to review.

How do daily Wegovy tablets fit into a GLP-1 routine?

Daily Wegovy tablets fit best when the tracker treats the pill as a repeatable morning routine, not a once-weekly event. The app should help you see adherence, dose progression, symptoms, weight trend, and food habits together so you can spot patterns without overinterpreting one noisy day.

Tablets trade injection-site tracking for adherence tracking

Wegovy tablets remove injection-site decisions, but they add daily adherence decisions. With weekly injections, many people focus on dose day, injection site, and weekly side effects. With tablets, the core routine is whether the pill was taken correctly each morning and whether any missed dose was handled according to instructions.

That means a pill tracker should not center on body maps or rotation. It should center on a daily checklist, current dose strength, missed-dose notes, and symptom timing. If you switch from injection to tablet, keep the old injection history for context, but start a separate daily pill habit.

Switching needs clinician instructions, not guesswork

Switching between Wegovy injection and Wegovy tablets should follow the FDA label and your prescriber's plan. The Wegovy label says patients taking Wegovy 2.4 mg injection for adult cardiovascular risk reduction or weight reduction may switch to Wegovy 25 mg tablets one week after discontinuing the injection.

That is not a general rule for every dose, every indication, or every patient. If your tracker shows an injection last week and a pill today, add a note such as "switched per prescriber" so the timeline is clear later. Do not use a tracker to calculate your own conversion.

Food, protein, and hydration notes add context

Food and hydration notes can help explain how you felt on a given day, especially when appetite changes after escalation. You do not need to log every bite to make the record useful; a short note about protein, water, nausea triggers, or skipped meals can be enough.

GlucoPal's nutrition tools can keep protein, calories, and water goals near your medication log, and AI meal scanning can estimate meal details from a photo when manual entry feels too slow. Keep those notes practical: they are context for patterns, not a substitute for clinical advice.

Weight trend matters more than daily noise

Weight tracking works best as a trend line, not a daily verdict. Wegovy tablet Study 7 in the FDA label reported a 13.6% least-squares mean body-weight reduction at week 64 with Wegovy 25 mg tablets versus 2.4% with placebo, but individual results vary and trial averages should not be treated as a personal forecast.

If you weigh daily, expect fluctuations from fluid, food timing, constipation, menstrual cycle changes, and scale conditions. A weekly average or recurring same-day weigh-in is usually easier to interpret than reacting to a single morning.

What should you avoid when tracking oral semaglutide?

Avoid using a Wegovy pill tracker to make medical decisions, double up after missed doses, combine semaglutide products, or normalize unverified "semaglutide pill" products. A tracker is a memory aid and pattern log; it should not replace the prescribing label, pharmacy instructions, or clinician guidance.

Do not double-dose after a missed tablet

Do not take extra Wegovy tablets to make up for a missed dose unless your clinician gives you a specific instruction. The FDA label's missed-dose instruction for Wegovy tablets is to skip the missed dose and take the next dose the following day.

Your tracker can make this easier by separating "missed" from "taken late." If you took the tablet late, log the actual time. If you skipped it, log "missed, skipped." That leaves a clean medication history without tempting you to fill the gap retroactively.

Do not combine GLP-1 medications unless prescribed

Do not stack Wegovy tablets with Wegovy injection, Rybelsus, Ozempic, compounded semaglutide, tirzepatide, or another GLP-1 medicine unless your prescriber specifically directs it. The Wegovy label says Wegovy should not be used with other semaglutide-containing products or other GLP-1 receptor agonists.

A tracker should make duplicate therapy visible. If two GLP-1 medications appear in the same week, that is a reason to check the plan with your care team, not a reason to assume the combination is intentional.

Be careful with compounded or online "semaglutide pills"

Be cautious with products marketed online as "semaglutide pills" if they are not the FDA-approved product your clinician prescribed and your pharmacy dispensed. FDA has repeatedly warned that compounded drugs are not FDA-approved, and the agency's semaglutide shortage update says semaglutide injection shortage conditions had resolved as of February 21, 2025.

This matters for tracking because a vague entry like "semaglutide pill" may hide whether you are taking Wegovy tablets, Rybelsus, or something else. Use the exact product name from the prescription label and keep photos or pharmacy records where your clinician can verify them.

Do not turn symptom tracking into self-diagnosis

Symptom tracking is useful when it helps you report timing, severity, and triggers clearly. It becomes risky when you use the log to rule out a serious problem on your own.

The Wegovy label includes warnings for issues such as pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury from volume depletion, hypoglycemia in some patients, hypersensitivity, diabetic retinopathy complications, heart-rate increase, suicidal behavior or thinking, and pulmonary aspiration risk during anesthesia or deep sedation. If symptoms are severe, unusual, or worrying, contact a healthcare professional.

If you want an iPhone log built around daily GLP-1 medication routines, GlucoPal is available on the App Store and can keep pill history, symptoms, weight trend, and nutrition notes in one place.

FAQ

Is Wegovy available as a pill in the US?

Yes. FDA approval documents and current prescribing information include Wegovy tablets as an approved oral semaglutide product in the US for specific adult indications. Access, insurance coverage, and clinical suitability still need to be handled by your prescriber and pharmacy.

What is the maintenance dose for Wegovy tablets?

The Wegovy prescribing information lists 25 mg orally once daily as the recommended maintenance dosage for adult cardiovascular risk reduction or weight reduction after escalation through lower tablet strengths. Follow your prescriber's plan if they delay or modify escalation.

What should I track for a daily Wegovy pill?

Track the tablet strength, time taken, whether it was missed or skipped, food-and-medication timing, side effects, weight trend, and notes about appetite, protein, water, or constipation. The best tracker is specific enough for clinical review but simple enough to use every day.

Can I track Rybelsus as Wegovy if both are semaglutide?

No. Track the exact prescribed product name and strength. Rybelsus and Wegovy tablets both contain semaglutide, but FDA labeling describes different products and labeled uses, so your app log should not treat them as interchangeable.

What should I do if I miss a Wegovy tablet?

The Wegovy label says to skip the missed tablet dose and take the next dose the following day. If you miss multiple doses, have side effects, or are unsure what happened, contact your prescriber or pharmacist for instructions.

Sources

1. FDA Approval Letter for Wegovy Tablets, NDA 218316 - FDA approval status and adult indications for Wegovy (semaglutide) tablets
2. FDA Wegovy Prescribing Information, revised March 2026 - tablet dosing schedule, missed-dose instructions, switching language, warnings, and Study 7 weight-loss data
3. FDA Rybelsus Prescribing Information, revised October 2025 - Rybelsus indications and oral semaglutide administration instructions used for product contrast
4. FDA GLP-1 Compounding and Shortage Update - FDA statements on semaglutide shortage resolution and compounded drug enforcement context